Summary
The kinetics of melphalan leakage into the peripheral blood were studied in 21 patients undergoing hyperthermic isolation perfusion of the upper or lower limb as an adjuvant treatment in high-risk melanoma; in 5 patients cisplatin was added. The melphalan concentrations in the peripheral blood rose predominantly during the first 20 min of perfusion and levelled out to an apparent steady state of about 0.28 μg/ml in upper extremity perfusions, and 0.34 (without cisplatin) and 0.37 μg/ml (with cisplatin) in lower extremity perfusions. Erythrocytes labelled with technetium Tc 99m, which were added concomitantly with melphalan to the perfusion medium, appeared in the systemic circulation of the patients at an almost constant rate of 0.32% (lower and upper limb perfusions without cisplatin and 0.37% (with cisplatin) of total tracer/min. This perfusate flow rate indicated by labelled erythrocytes completely explained the leakage of melphalan from the perfusion circuit into the peripheral blood. Peak concentrations of melphalan in the peripheral blood were observed immediately after reconstitution of normal hemodynamic conditions once isolation perfusion had been teminated. This fraction of melphalan might originate from tissue-binding sites, but also from vascular compartments; therefore, a thorough washing-out procedure might minimize this effect.
Similar content being viewed by others
References
Ardiet C, Tranchand B, Biron P, Rebattu P, Philip T (1986) Pharmacokinetics of high-dose intravenous melphalan in children and adults with forced diuresis (report in 26 cases). Cancer Chemother Pharmacol 16: 300
Barcroft H (1963) Circulation in skeletal muscle. In: Handbook of physiology, vol II Circulation. Americal Physiology Society, Washington, p 1353
Bauer R, Bauer U, Sauer E, Langhammer H, Pabst HW (1981) In vivo/in vitro-Markierung von Erythrozyten mit99mTc und ihre klinische Anwendung. Nucl Compact 12: 18–25
Benckhuisen C, Varossieau FJ, Hart AAM, Wieberdink J, Noordhoek J (1986) Pharmacokinetics of melphalan in isolated perfusion of the limbs. J Pharmacol Exp Ther 237: 583
Benet LZ, Sheiner LB (1985) Design and optimization of dosage regimens; pharmacokinetic data. In: Goodman S, Gilman A (eds), The pharmacological basis of therapeutics, 7th edn. Macmillan, New York, p 1663
Bosanquet AGA, Gilby ED (1982) Pharmacokinetics of oral and intravenous melphalan during routine treatment of multiple myeloma. Eur J Cancer Clin Oncol 18: 355
Ehrsson H, Ekborg S, Osterborg A, Mellstedt H, Lindfors A (1989) Oral melphalan pharmacokinetics — relation to dose in patients with multiple myeloma. Med Oncol Tumor Pharmacother 6: 151
Gera S, Musch E, Osterheld HKO, Loos U (1989) Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma. Cancer Chemother Pharmacol 23: 76
Ghussen F, Nagel K, Groth W, Müller JM, Stützer H (1984) A prospective randomized study of regional extremity perfusions in patients with malignant melanoma. An Surg 200: 764
Gouyette A, Hartmann O, Pico JL (1986) Pharmacokinetics of high-dose melphalan in children and adults. Cancer Chemother Pharmacol 16: 184
Hafström L, Hugander A, Jönsson PE, Westling H, Ehrsson H (1984) Blood leakage and melphalan leakage from the perfusion circuit during regional hyperthermic perfusion for malignant melanoma. Cancer Treat Rep 68: 867
Krementz ET, Carter RD, Sutherland CM, Muchmore JH (1987) Chemotherapy by regional perfusion for limb melanoma. Am Surg 53: 133
Lejeune FJ, Ghanem EG (1987) A simple and accurate new method for cytostatics dosimetry in isolation perfusion of the limbs based on exchangeable blood volume determination. Cancer Res 47: 639
Martijn H, Schrafford Koops H, Milton GW, Nap M, Oosterhuis JW, Shaw HM, Oldhoff J (1986) Comparison of two methods of treating primary malignant melanomas Clark IV and V, thickness 1.5 mm and greater, localized on the extremities. Wide surgical excision with and without adjuvant regional perfusion. Cancer 57: 1923
Milnor WR (1974) In: Mountcastle VB (ed) Medical physiology 13. Mosby, St. Louis
Minor DR, Allen RE, Alberts D, Peng YM, Tardelli G, Hutchinson J (1985) A clinical and pharmacokinetic study on isolated limb perfusion with heat and melphalan for melanoma. Cancer 55: 2638
Rege VB, Leone AL, Soderberg CH, Coleman GV, Robidoux HJ, Fijman R, Brown J (1983) Hyperthermic adjuvant perfusion chemotherapy for stage I malignant melanoma of the extremity with literature review. Cancer 52: 2033
Taha IA, Ahmad RA, Gray H, Roberts CI, Rogers HJ (1982) Plasma melphalan and prednisolone concentrations during oral therapy for multiple myeloma. Cancer Chemother Pharmacol 9: 57
Woodhouse KW, Henderson DB (1981) High pressure liquid chromatographic method for the determination of melphalan in plasma. Proceedings, Meeting of the British Pharmacological Society, December 16–18, p 605
Woodhouse KW, Hamilton P, Lennard A, Rawlins MD (1983) The pharmacokinetics of melphalan in patients with multiple myeloma: an intravenous/oral study using a conventional dose regimen. Eur J Clin Pharmacol 24: 283
Zucchetti M, D'Incalci M, Willems Y, Cavalli F, Sessa C (1988) Lack of effect of cisplatin on i. v.l-PAM plasma pharmacokinetics in ovarian cancer patients. Cancer Chemother Pharmacol 22: 87
Author information
Authors and Affiliations
Additional information
This study was supported by the Deutsche Krebshilfe/Dr. Mildred Scheel Stiftung, Bonn-Bad Godesberg, FRG
Rights and permissions
About this article
Cite this article
Rauschecker, H.F., Foth, H., Michaelis, H.C. et al. Kinetics of melphalan leakage during hyperthermic isolation perfusion in melanoma of the limb. Cancer Chemother. Pharmacol. 27, 379–384 (1991). https://doi.org/10.1007/BF00688861
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00688861